Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

ResMed Inc.Trade
iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? ResMed Inc. trades at $226.27 (market cap $32.61B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.12. The key difference: ResMed Inc. pays a 1.17% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and ResMed Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

RMDTLT
Market Cap
$32.61B
Sector
Health
52-Week High
$293.73$92.06
52-Week Low
$182.82$82.05
Enterprise Value
$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

iShares 20 Plus Year Treasury Bond ETF

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.29 with a slight 0.3% daily gain amid bearish technical signals. The ETF faces pressure from rising long-term Treasury yields, with the 30-year yield recently hitting 5.24% (The Motley Fool, 2026-08-02). Institutional interest persists as Ferguson Shapiro LLC acquired 37,900 shares (Defense World, 2026-08-10), but outflows and U.S. debt nearing $40 trillion weigh on sentiment.

Outlook remains cautious as higher yields and inflation concerns challenge TLT's performance. Opportunities exist for income-focused investors given dividend payments, but risks include Fed rate hike potential and escalating geopolitical tensions driving oil prices higher. The bearish technical setup suggests continued pressure unless bond market sentiment improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.

Read more on TLT